Literature DB >> 22889973

Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect.

Hussein A Tawbi, John M Kirkwood.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889973     DOI: 10.1038/nrclinonc.2012.138

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

3.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

4.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Authors:  Gerald S Falchook; Georgina V Long; Razelle Kurzrock; Kevin B Kim; Tobias H Arkenau; Michael P Brown; Omid Hamid; Jeffrey R Infante; Michael Millward; Anna C Pavlick; Steven J O'Day; Samuel C Blackman; C Martin Curtis; Peter Lebowitz; Bo Ma; Daniele Ouellet; Richard F Kefford
Journal:  Lancet       Date:  2012-05-19       Impact factor: 79.321

5.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

6.  Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.

Authors:  Axel Hauschild; Sanjiv S Agarwala; Uwe Trefzer; David Hogg; Caroline Robert; Peter Hersey; Alexander Eggermont; Stephan Grabbe; Rene Gonzalez; Jens Gille; Christian Peschel; Dirk Schadendorf; Claus Garbe; Steven O'Day; Adil Daud; J Michael White; Chenghua Xia; Kiran Patel; John M Kirkwood; Ulrich Keilholz
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

7.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

  7 in total
  4 in total

1.  ETV1-Positive Cells Give Rise to BRAFV600E -Mutant Gastrointestinal Stromal Tumors.

Authors:  Leili Ran; Devan Murphy; Jessica Sher; Zhen Cao; Shangqian Wang; Edward Walczak; Youxin Guan; Yuanyuan Xie; Shipra Shukla; Yu Zhan; Cristina R Antonescu; Yu Chen; Ping Chi
Journal:  Cancer Res       Date:  2017-05-24       Impact factor: 12.701

2.  Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo.

Authors:  Jiaxuan Song; Yoshiaki Kobayashi; Yoshimasa Asano; Atsushi Sato; Hiroaki Taniguchi; Kumiko Ui-Tei
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

3.  Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.

Authors:  Thomas E Delea; Jordan Amdahl; Alice Wang; Mayur M Amonkar; Marroon Thabane
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

Review 4.  Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma.

Authors:  Suzanne McGettigan
Journal:  J Adv Pract Oncol       Date:  2014-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.